Helus Pharma CEO to Discuss Mental Health Drug Pipeline at Cantor Conference
Event summary
- Helus Pharma CEO Michael Halstead to participate in fireside chat at Cantor Global Healthcare Conference on September 11, 2026.
- Company developing HLP003 (Phase 3) for major depressive disorder with FDA Breakthrough Therapy Designation.
- HLP004 in Phase 2 trials for generalized anxiety disorder.
- Helus Pharma operates in Canada, US, UK, and Ireland.
The big picture
Helus Pharma's conference appearance comes as the mental health drug market faces increasing demand for novel treatments. The company's focus on serotonergic agonists positions it in a growing segment of neuroplasticity-focused therapies. Success in Phase 3 trials for HLP003 could significantly impact its market valuation and competitive standing.
What we're watching
- Regulatory Progress
- Whether HLP003 can maintain Breakthrough Therapy status through Phase 3 trials.
- Pipeline Momentum
- The pace of HLP004's advancement through Phase 2 trials for anxiety treatment.
- Market Positioning
- How Helus Pharma differentiates its serotonergic agonists in a competitive mental health drug landscape.
Related topics